PHARMACOLOGY IV – HEADACHE THERAPEUTICS PRACTICE TEST (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://pharm4headachetherapeutics.examzify.com

Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright 1

Table of Contents 2

Introduction 3

How to Use This Guide 4

Questions 5

Answers 9

Explanations 11

Next Steps 16

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

SAMPLE

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

SAMPLE

Questions

SAMPLE

1. What is one reason that pediatric dosing differs from adult dosing?

A. Children have different weights and developmental changes affecting pharmacokinetics.

B. Children metabolize drugs identically to adults.

C. Pediatric patients require larger doses.

D. There is no need for age-specific guidelines.

2. Which of the following is a secondary cause to consider in the differential diagnosis of migraine?

A. Head/neck trauma

B. Tension-type headache

C. Cluster headache

D. All headaches

3. Which statement correctly distinguishes gepants from monoclonal antibodies in CGRP-targeted therapy?

A. Gepants are oral CGRP receptor antagonists

B. Umabs are CGRP monoclonal antibodies

C. Both statements are correct

D. None of the above

4. What is first-line therapy for mild to moderate acute episodic migraine?

A. Triptans as first-line

B. Opioids as first-line

C. Corticosteroids as first-line

D. Non-opioid analgesics such as acetaminophen or NSAIDs (with or without caffeine)

5. Which condition is a contraindication to triptan therapy?

A. Uncontrolled hypertension

B. Migraine with aura

C. Asthma

D. Controlled hypertension

SAMPLE

6. Which statement about diagnostic testing for migraine is true?

A. Neuroimaging is routinely required in all patients.

B. A comprehensive psychiatric evaluation is sufficient.

C. Neuroimaging is not necessary in most patients with migraine; perform a general medical and neurologic exam; check for abnormalities (vital signs, fundoscopy, palpation and auscultation of head/neck, neurological examination)

D. No testing is ever needed.

7. Which pair of lifestyle factors is commonly recommended to avoid in migraine management?

A. Dehydration and sleep disturbance.

B. Adequate hydration and regular sleep.

C. Caffeine withdrawal and increased stress.

D. Regular exercise and hydration.

8. What is the role and typical dose of riboflavin in migraine prevention?

A. Riboflavin 200 mg daily shown potential benefit for reducing migraine frequency; well tolerated.

B. Riboflavin 400 mg daily shown potential benefit for reducing migraine frequency; well tolerated.

C. Riboflavin 50 mg daily

D. Riboflavin is not used in migraine prevention

9. Considering pediatric migraine treatment, the statement 'some triptans have pediatric approvals with weight-based dosing' implies which of the following?

A. Pediatric dosing is fixed and not influenced by weight.

B. All triptans are approved for children with identical dosing.

C. Dosing for children should be guided by age/weight-specific guidelines and safety data.

D. Pediatric triptans should never be used.

SAMPLE

10. In pediatric migraine treatment, what is true about approved therapies and dosing?

A. Some triptans have pediatric approvals with weight-based dosing; dosing for children requires age/weight-specific guidelines and pediatric safety data.

B. All triptans used in children are approved with identical dosing to adults.

C. No triptans are approved for pediatric use.

D. Pediatric migraine therapy relies exclusively on non-drug approaches.

SAMPLE

Answers

SAMPLE

1. A
2. A
3. C
4. D
5. A
6. C
7. A
8. B
9. C
10. A

SAMPLE

Explanations

SAMPLE

1. What is one reason that pediatric dosing differs from adult dosing?

A. Children have different weights and developmental changes affecting pharmacokinetics.

B. Children metabolize drugs identically to adults.

C. Pediatric patients require larger doses.

D. There is no need for age-specific guidelines.

Pediatric dosing differs because children's bodies are not just smaller versions of adults; growth and development change how drugs move through and are processed by the body. Weight is a key factor, but age-related maturation of organs and physiology alters pharmacokinetics in several ways. Infants have more body water and less fat, which affects how hydrophilic versus lipophilic drugs distribute. Absorption can vary due to immature gastric pH and slower or irregular gastric emptying. Metabolism depends on liver enzyme systems that mature at different rates, so some drugs are metabolized more slowly in younger children. Renal clearance also increases with age as kidney function matures, changing how quickly drugs are eliminated. Because these factors shift during development, dosing is typically expressed in mg per kg (and sometimes adjusted for body surface area or age), with careful monitoring. That's why the idea that children metabolize drugs identically to adults isn't correct, and why dosing isn't universally larger in kids. Age-specific guidelines exist precisely because maturation affects pharmacokinetics and, consequently, dosing and safety.

2. Which of the following is a secondary cause to consider in the differential diagnosis of migraine?

A. Head/neck trauma

B. Tension-type headache

C. Cluster headache

D. All headaches

When evaluating a migraine presentation, it's essential to consider secondary headaches—headaches caused by another underlying condition. Head/neck trauma fits here because a post-traumatic headache can resemble migraine or trigger migraine-like symptoms, so a patient with a history of head or neck injury warrants careful assessment to rule out trauma-related pathology or secondary processes. Tension-type headache and cluster headache are primary headache disorders—they occur independently of another condition and are not considered secondary causes in this differential. "All headaches" isn't a specific etiologic category to point to as a secondary cause. The key is identifying headaches that arise as a consequence of another issue, with head/neck trauma being the classic example among the options.

3. Which statement correctly distinguishes gepants from monoclonal antibodies in CGRP-targeted therapy?

A. Gepants are oral CGRP receptor antagonists

B. Umabs are CGRP monoclonal antibodies

C. Both statements are correct

D. None of the above

Gepants and monoclonal antibodies inhibit the CGRP pathway in migraine, but they differ in form and administration. Gepants are oral small molecules that block the CGRP receptor, preventing CGRP signaling after you take them. Monoclonal antibodies against CGRP are large proteins given by injection and can target either the CGRP ligand or the CGRP receptor, resulting in long-lasting CGRP pathway inhibition with infrequent dosing. The statement that gepants are oral CGRP receptor antagonists is correct, and the statement that CGRP monoclonal antibodies (Umabs) are CGRP monoclonal antibodies is also correct. Therefore, both statements are true.

SAMPLE

4. What is first-line therapy for mild to moderate acute episodic migraine?

A. Triptans as first-line

B. Opioids as first-line

C. Corticosteroids as first-line

D. Non-opioid analgesics such as acetaminophen or NSAIDs (with or without caffeine)

For mild to moderate acute episodic migraine, the goal is rapid relief with a therapy that is effective yet has a favorable safety profile. Non-opioid analgesics such as acetaminophen or NSAIDs address the pain and inflammatory components of migraine and tend to work quickly, making them suitable as first-line options. When these are used with caffeine, the analgesic effect can be enhanced and relief can occur sooner, which is why many OTC products combine analgesics with caffeine. Triptans are effective for many patients, but they're often reserved for more prominent or disabling attacks or when NSAIDs alone aren't enough, because of cost, tolerability, and potential cardiovascular or drug-interaction concerns. Opioids are not preferred first-line due to risks of dependence, misuse, side effects, and a higher chance of headache chronification with overuse. If the initial non-opioid approach isn't sufficient, escalation to a triptan (alone or with NSAID) can be considered, always guided by individual safety factors and comorbidities.

5. Which condition is a contraindication to triptan therapy?

A. Uncontrolled hypertension

B. Migraine with aura

C. Asthma

D. Controlled hypertension

Triptans work by activating 5-HT1B/1D receptors to cause cranial vasoconstriction and to inhibit neuropeptide release, helping alleviate migraine pain. In someone with uncontrolled hypertension, this additional vasoconstriction can raise blood pressure further and increase the risk of cardiovascular events such as stroke or myocardial ischemia. That's why uncontrolled hypertension is a contraindication to triptan therapy. Migraine with aura alone is not a blanket contraindication; the decision depends on overall cardiovascular risk, but aura by itself does not automatically preclude use. Asthma is not a contraindication for most patients. Controlled hypertension is compatible with triptan use, often with standard precautions.

SAMPLE

6. Which statement about diagnostic testing for migraine is true?

A. Neuroimaging is routinely required in all patients.

B. A comprehensive psychiatric evaluation is sufficient.

C. Neuroimaging is not necessary in most patients with migraine; perform a general medical and neurologic exam; check for abnormalities (vital signs, fundoscopy, palpation and auscultation of head/neck, neurological examination)

D. No testing is ever needed.

In diagnosing migraine, the key idea is that it is a clinical syndrome: most cases are identified from the patient's history and a thorough neurologic exam, not from routine imaging. If the presentation is typical—recurrent, pulsating headaches with nausea, photophobia, possibly aura—and the neurologic exam is normal, imaging adds little and can lead to unnecessary costs and incidental findings. Therefore, the recommended approach is to perform a general medical evaluation and a comprehensive neurologic exam to look for red flags. Imaging is reserved for situations that raise concern for a secondary headache, such as a sudden thunderclap onset, new headaches in someone over age 50 or with a change in headache pattern, focal neurologic deficits, fever or signs of infection, or a history of trauma or cancer that might suggest an alternative diagnosis. In the absence of these red flags, imaging is not needed. Psychiatric evaluation is important for addressing comorbidities, but it does not replace the need for a full medical and neurologic assessment when diagnosing headache. And saying no testing is ever needed would be incorrect, since some patients do require imaging to exclude other serious conditions.

7. Which pair of lifestyle factors is commonly recommended to avoid in migraine management?

A. Dehydration and sleep disturbance.

B. Adequate hydration and regular sleep.

C. Caffeine withdrawal and increased stress.

D. Regular exercise and hydration.

The idea here is that migraine is often triggered by modifiable lifestyle factors, and two of the most consistently reported triggers are not drinking enough water and irregular or disturbed sleep. Dehydration can lower blood volume and affect cerebral perfusion and vascular tone, making a migraine more likely. Sleep disturbance disrupts circadian rhythms and increases brain excitability, lowering the threshold for a migraine attack. Together, they commonly precipitate attacks, so avoiding these factors—staying well hydrated and keeping a regular sleep schedule—is a straightforward, effective part of migraine management. The other options include factors that are either generally protective (adequate hydration and regular sleep; regular exercise and hydration) or that only trigger migraines in some people (caffeine withdrawal, increased stress). But the pair most widely recommended to avoid for reducing attack risk is dehydration and sleep disturbance.

SAMPLE

8. What is the role and typical dose of riboflavin in migraine prevention?

A. Riboflavin 200 mg daily shown potential benefit for reducing migraine frequency; well tolerated.

B. Riboflavin 400 mg daily shown potential benefit for reducing migraine frequency; well tolerated.

C. Riboflavin 50 mg daily

D. Riboflavin is not used in migraine prevention

High-dose riboflavin helps migraine prevention by supporting mitochondrial energy production in brain cells, which may reduce neuronal susceptibility to migraine attacks. The most robust evidence supports using about 400 mg per day, typically given in divided doses to improve tolerability. In randomized trials, this dose has been associated with a meaningful reduction in migraine attack frequency and is generally well tolerated, with the most common benign effect being bright yellow urine. Lower doses, such as 50 mg daily, are not consistently effective, and 200 mg daily has less robust data compared to 400 mg. Start this regimen and reassess after about 3 months to determine response.

9. Considering pediatric migraine treatment, the statement 'some triptans have pediatric approvals with weight-based dosing' implies which of the following?

A. Pediatric dosing is fixed and not influenced by weight.

B. All triptans are approved for children with identical dosing.

C. Dosing for children should be guided by age/weight-specific guidelines and safety data.

D. Pediatric triptans should never be used.

Dosing in pediatric migraine treatment is shaped by the child's weight because children process drugs differently from adults and even from older kids. When a triptan has pediatric approval with weight-based dosing, it means clinicians use the child's weight (often with weight bands or mg/kg guidance) to determine the dose, rather than giving the same amount to every child. This approach, grounded in pediatric safety and efficacy data, helps ensure the medication relieves the headache without increasing the risk of adverse effects. So, the implication is that dosing should be guided by weight-specific guidelines and the supporting safety data, not by a one-size-fits-all dose.

10. In pediatric migraine treatment, what is true about approved therapies and dosing?

A. Some triptans have pediatric approvals with weight-based dosing; dosing for children requires age/weight-specific guidelines and pediatric safety data.

B. All triptans used in children are approved with identical dosing to adults.

C. No triptans are approved for pediatric use.

D. Pediatric migraine therapy relies exclusively on non-drug approaches.

In pediatric migraine management, not all triptans are treated the same as in adults. Some triptans have official approvals for use in children, and when they are prescribed, the dose is tailored to the child's age and weight. Children process drugs differently from adults, so dosing guidelines are designed around specific weight bands and age ranges, backed by pediatric safety data. This means adult dosing cannot be assumed for children, and clinicians rely on age- and weight-based recommendations. That's why the statement stating that some triptans have pediatric approvals with weight-based dosing and require age/weight-specific guidelines and safety data is the best choice.

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://pharm4headachetherapeutics.examzify.com

We wish you the very best on your exam journey. You've got this!

SAMPLE